Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX13 vs YERVOY PK Study in Healthy Chinese Males
NCT06159101Phase 1Recruiting
- Sponsor
- Henlius
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HLX13 in melanoma, hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and 1 more (4 arms), sponsored by Henlius. Primary endpoints: Area under the serum concentration-time curve from time 0 to infinity and Maximum serum drug concentration. Started Nov 2023; status: recruiting.
02
Drugs
HLX13
03
Conditions
melanomahepatocellular carcinoma (HCC)renal cell carcinoma (RCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06159101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06159101.